KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Inventory (2016 - 2024)

Nektar Therapeutics has reported Change in Inventory over the past 15 years, most recently at -$1.3 million for Q4 2024.

  • Quarterly results put Change in Inventory at -$1.3 million for Q4 2024, down 21.85% from a year ago — trailing twelve months through Sep 2025 was -$1.3 million (down 396.2% YoY), and the annual figure for FY2024 was -$497000.0, up 28.9%.
  • Change in Inventory for Q4 2024 was -$1.3 million at Nektar Therapeutics, down from -$123000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for NKTR hit a ceiling of $2.4 million in Q4 2020 and a floor of -$2.4 million in Q3 2023.
  • Median Change in Inventory over the past 5 years was $389500.0 (2020), compared with a mean of $267050.0.
  • Peak annual rise in Change in Inventory hit 570.38% in 2023, while the deepest fall reached 838.62% in 2023.
  • Nektar Therapeutics' Change in Inventory stood at $2.4 million in 2020, then crashed by 80.38% to $471000.0 in 2021, then plummeted by 69.21% to $145000.0 in 2022, then plummeted by 838.62% to -$1.1 million in 2023, then dropped by 21.85% to -$1.3 million in 2024.
  • The last three reported values for Change in Inventory were -$1.3 million (Q4 2024), -$123000.0 (Q3 2024), and -$212000.0 (Q2 2024) per Business Quant data.